Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and ...

HSBC upgraded Dr Reddy’s Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk’s blockbuster ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Novo Nordisk ( NVO 1.27%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.